Most business plan guidance assumes you are opening something. A shop, a clinic, a practice. You sign a lease, buy equipment, hire staff, open the doors, and revenue starts in month one. Nearly every generic template on the internet is built on that skeleton, which is why so many of them quietly mislead anyone working in cancer immunotherapy.

An immuno-oncology venture does not work like that. You are not opening anything. You are financing a scientific hypothesis through a sequence of regulatory gates, and the first dollar of product revenue may be eight to twelve years away, if it arrives at all. The plan that gets funded is not the one showing a tidy profit in year two. It is the one that proves the founder understands exactly which gate they are raising against, what that gate costs, what evidence clears it, and what the money buys between now and the next one.

This guide is written for that reality. It covers the capital required to reach an Investigational New Drug application, the regulatory route through the FDA, the MHRA and the EMA, the vendors you will actually be writing cheques to, and the unit economics of a cell therapy once it does reach market. The numbers below are sourced and linked. Where a figure is a range across research houses that disagree, we show the disagreement rather than picking the flattering number, because a specialist investor will know the spread and will notice if you do not.

Bench To IND: A 36-Month Launch Timeline

The single most useful structural decision you can make in a cancer immunotherapy business plan is to organise it around capital gates rather than calendar years. Investors in this sector do not think in fiscal years. They think in milestones: what does this money buy, and what will be true at the end of it that is not true today?

Below is a representative path from a university bench result to a filed IND for an autologous cell therapy. Timelines compress or stretch depending on modality, but the gate sequence rarely changes. IND-enabling studies alone typically take around 18 months and require coordination across several scientific disciplines, according to GMP Pros, 2025.

Months 0–6: Formation and IP

• Secure the licence from the institution. If the science came out of a university lab, the technology transfer office owns it until a licence agreement says otherwise. Term sheets here routinely take four to six months and set royalty stacking that will follow the company through every downstream deal.
• Freedom-to-operate analysis. Immuno-oncology is one of the most densely patented fields in biology. A construct that works at the bench may be unlicensable commercially. Find out before you raise, not during diligence.
• Corporate structure. Founders raising from US funds commonly place a Delaware topco above a UK operating subsidiary. Decide early, because unwinding it later is expensive.
• Founder and advisory board assembly. A strong scientific advisory board is not decoration. It is the primary credibility signal a preclinical company has.

Months 6–12: Proof of concept and first non-dilutive money

• In vivo efficacy in a relevant model. This is the minimum evidence bar for a serious seed conversation.
• File an NCI SBIR Phase I application. Phase I awards run $300K to $400K over roughly one year for proof-of-concept work, per Biocom / NCI SBIR, 2025. Omnibus deadlines fall on 5 January, 5 April and 5 September.
• Book a pre-IND meeting slot. These are scheduled months out. The meeting itself is free and is the highest-return hour available to a preclinical company.
• Select your CDMO. Not sign, select. GMP slots are booked twelve to eighteen months ahead, and founders who treat manufacturing capacity as commodity procurement discover in month 20 that nobody can make their drug.

Months 12–30: IND-enabling package

• GLP toxicology. The long pole in the tent. Study design should have been agreed at the pre-IND meeting.
• CMC development. For a cell therapy this means locking the process, the analytics and the release assays. The FDA applies deliberately flexible CMC expectations to cell and gene therapy products, because patient-specific manufacturing, short shelf lives and limited batch quantities do not fit frameworks designed for conventional biologics (The FDA Group, 2026). Flexible does not mean lenient. It means you must argue your case rather than tick a box.
• Engineering runs at the CDMO. Budget for at least two. The first one will teach you something unwelcome.
• SBIR Phase II or seed round. Phase II provides up to $2.25M over two years, with a Phase IIB Bridge Award of $4.5M over two to three years available to companies moving toward commercialisation.

Months 30–36: File and prepare for first-in-human

• Submit the IND to CBER. A 30-day review clock starts on receipt. Silence at day 30 means you may proceed.
• Clinical site selection and contracting. Academic medical centres with existing cell therapy infrastructure will move faster than sites building capability for you.
• Long-term follow-up plan. Products using integrating vectors carry a 15-year patient follow-up obligation. This is a real, funded, multi-decade cost line that founders routinely omit from the model entirely.

Write this sequence into the plan as a gated milestone chart with a capital requirement attached to each gate. It replaces the fictional revenue ramp that generic templates ask for, and it is the section experienced investors read first.

What Reaching An IND Really Costs

Ask the internet what it costs to start a cancer immunotherapy business and you will get numbers in the low hundreds of thousands. Those numbers are for medical practices that administer immunotherapy, not for companies that develop it. If you are developing, the honest answer is that a credible seed-to-IND budget for an advanced modality sits somewhere between $2.5M and $12M (£2M to £9.5M), and the spread is driven almost entirely by modality and manufacturing complexity.

The anchor figure: IND-enabling packages for small molecules typically range from $2M to $7M, while biologics and advanced modalities routinely exceed that range because of added complexity in study design, bioanalysis, manufacturing and toxicology (GMP Pros, 2025). Cancer immunotherapy sits squarely in the expensive half. A CAR-T or TCR programme carries vector work, a closed manufacturing process and patient-specific quality control that a small molecule simply does not have.

The line items founders forget

• Engineering and validation runs. Not one batch. Several, and each one at a CDMO is priced like a commercial batch.
• Comparability studies. Change your process after tox and you may owe the agency a bridge.
• 15-year long-term follow-up. For integrating vectors this obligation attaches at first dosing and does not end when the trial does.
• Insurance for a first-in-human trial. Materially more expensive than founders assume.
• Runway past the gate. Filing an IND with three months of cash left is not a milestone, it is a fire sale. Investors price that.

Funding routes that actually apply

Generic templates will tell you about SBA 7(a) loans and equipment financing. Neither is realistic for a pre-revenue therapeutics company with no collateral and no path to servicing debt. Here is what founders in this niche actually use.

• NCI SBIR Phase I: $300K–$400K over about a year for proof of concept. Non-dilutive.
• NCI SBIR Phase II: up to $2.25M over two years of R&D.
• NCI SBIR Phase IIB Bridge: $4.5M over two to three years, designed for the gap between grant-funded research and commercial capital (Biocom / NCI SBIR, 2025).
• NIH standard budget guidelines: Phase I $323,090 and Phase II $2,153,927, though individual institutes set their own limits (PreVeil, 2025).
• Venture seed: typically follows in vivo proof of concept, not precedes it.
• Series A: median round sizes returned to $50M–$80M across 2025 and 2026, and the bar is validated preclinical data plus a credible IND-enabling plan (Vision Life Sciences, 2026). Real examples: Nilo Therapeutics raised $101M in a 2025 Series A for lab build-out and pipeline; Umoja Biopharma's $210M Series B was led by SoftBank Vision Fund 2 and Cormorant Asset Management.
• UK non-dilutive: Innovate UK grants and the Cell and Gene Therapy Catapult ecosystem, plus SEIS and EIS relief which materially changes the calculus for UK angel investors.

Stacked SBIR awards can carry a company to roughly $6.7M of non-dilutive funding before a priced round. For a lean, well-scoped programme that is genuinely most of the way to an IND, and it is the single most under-exploited route in this sector. Our market research and content service is frequently used to build exactly this section, because grant reviewers and venture investors want the same evidence presented in very different registers.

CDMOs, CROs And Platform Vendors You Will Actually Use

A business plan that says "we will outsource manufacturing" and stops there tells a reader nothing. In cell therapy, the vendor list is the operations plan. Capacity is scarce, switching costs are brutal, and your choice of platform partly determines your regulatory filing. Name your vendors, state where you are in the conversation with each, and say what happens if your first choice cannot take you.

On price: CDMO per-batch or per-patient manufacturing for autologous therapies runs $100,000 to $500,000, depending on vector type, complexity and facility location, according to DrugPatentWatch, 2025. That is per patient. Not per production run serving thousands of patients. Per patient.

This is the fact that reshapes everything downstream. For autologous therapies, one manufacturing batch produces product for exactly one patient, so there are no economies of scale and a CDMO cannot amortise process development across ten thousand commercial batches. Analysis in BioProcess International puts autologous CAR-T manufacturing at $100,000 to $300,000 per dose, with labour alone contributing more than half of that cost.

If your plan assumes cost per dose falls with volume, you have quietly written an allogeneic business plan while filing an autologous product. That contradiction is visible to any specialist reader within about ninety seconds, and it is the most common fatal flaw we see in this niche.

Regulatory Route: FDA, MHRA And The EU

In most industries the licensing section of a business plan is a formality. Here it is the business. Your regulatory strategy determines your timeline, your burn, your value inflection points and, in several jurisdictions, whether an entirely different commercial route is open to you.

United States

Cancer immunotherapies of the cell and gene variety are regulated by CBER as biological products under Section 351 of the Public Health Service Act. That means an IND to investigate and a Biologics License Application to market. The Office of Tissues and Advanced Therapies reviews the CMC, pharmacology and toxicology data (Assyro, 2026).

• IND application (FDA CBER). 30-day review clock. Preceded by an IND-enabling package costing $2M–$7M and up, over roughly 18 months.
• BLA under Section 351. The marketing authorisation. As of March 2026 the FDA had approved seven CAR-T products through CBER, all of them autologous. Multiple allogeneic candidates are in clinical development and none has yet reached BLA approval.
• Chain of identity and chain of custody. Unique to autologous products and non-negotiable. You are shipping one patient's cells and they must come back to that patient.
• Vector characterisation and starting-material requirements. Frequently the gating CMC issue.
• Release testing under time pressure. A fresh autologous product has a short shelf life. Your release assays must fit inside it, which constrains which assays you can use at all.
• Long-term follow-up. 15 years for integrating vectors.

That "all seven are autologous" fact deserves a line in your plan. If you are building allogeneic, you are pursuing a route nobody has completed, which is either your central value proposition or an unpriced risk. Investors will want to know which.

United Kingdom

The UK is a dual-regulator jurisdiction, and this is the detail founders miss most often. The MHRA regulates the medicinal product. The Human Tissue Authority regulates the donation, procurement and testing of the cells you start from. The HTA and MHRA collaborate to ensure tissues and cells used in ATMP manufacture meet safety and quality standards (ElendiLabs). A plan that names only the MHRA signals that the founder has not yet spoken to a UK regulatory consultant.

• Clinical Trial Authorisation from the MHRA, which assesses quality, safety and trial design (GOV.UK).
• ATMP regulation and licensing via the MHRA (GOV.UK).
• HTA licence covering procurement and testing of the human starting material.
• International Recognition Procedure. Launched January 2024. Products already approved in the US, EU/EEA, Australia, Canada, Switzerland, Singapore or Japan can take an abbreviated review, with a Recognition B route running a 110-day review timeline for ATMPs. NICE appraisal is cut by roughly half, and HTA assessment follows around 90 days after MHRA approval (Cell & Gene Therapy / Taylor & Francis, 2024).
• MHRA Innovation Office. Free regulatory advice for early-stage innovative products. Free. Use it, and say in your plan that you have.

The IRP has a strategic implication worth writing down explicitly: for a UK company, approving in the US first and recognising into the UK afterwards can be faster and cheaper than a parallel filing. That is a sequencing decision with real cash consequences and it belongs in the plan, not in a footnote.

European Union

ATMPs in the EU run through a centralised marketing authorisation at the EMA under Regulation (EC) No 1394/2007, which entered into force on 30 December 2008 and established the first EU-wide framework for advanced therapies. Authorisation can be granted three ways: standard, conditional, or under exceptional circumstances, with the route depending on the extent of clinical data and whether the medicine addresses an unmet need (Molecular Therapy: Methods & Clinical Development, 2019). The PRIME scheme, introduced in 2016, offers enhanced scientific advice, early rapporteur appointment and accelerated assessment eligibility.

Then there is the route almost no business plan mentions. Article 28 of Regulation 1394/2007 creates a hospital exemption: an EU hospital may manufacture and administer an ATMP, including a CAR-T, without a centralised EMA marketing authorisation, provided the product is custom-made, non-routine, prescribed for an individual patient, and used in the same Member State where it is made. It is a national pathway rather than a centralised one, and 19 of 27 Member States had an operational framework as of 2025. The Spanish CAR-T ARI-0001 is the standing proof that the route works in practice (NCBI PMC).

For an academic-adjacent founder with a hospital partner, hospital exemption can generate real clinical experience and real patient outcomes years before a centralised authorisation is plausible. It will not build a scalable company on its own, and it is not a shortcut to a BLA. But as a de-risking and evidence-generating step it is badly underused, and naming it in a plan demonstrates a depth of regulatory literacy that most first-time founders do not display.

Where The Money Comes From, And When

Here is the sentence that costs founders the most money in this sector: a clinical-stage immuno-oncology company has a deeply negative net margin by design, and that is correct, not a problem to be hidden. When a first-time founder submits a plan showing 18% net margin in year two, a specialist investor does not conclude that the company is efficient. They conclude the founder does not understand their own cost structure, and the meeting is effectively over.

What you model instead is the gross margin of the product at maturity, the burn required to get there, and the volume at which the two cross.

What approved products actually sell for

US 2025 wholesale acquisition cost list prices, per HMPI, 2026:

WAC excludes discounts, rebates and outcome-based adjustments, so net realised price is lower. It is also not the whole cost of care. Median total costs during the CAR-T treatment period were $608,100, of which the product itself was $402,500 and the median patient out-of-pocket copayment was $510 (NCBI PMC). That gap between product price and episode cost is where payer resistance lives, and your market access section needs to speak to it.

A worked unit-economics example

Take a CD19 CAR-T priced at Yescarta's $373,000 WAC, with a fully-loaded COGS of $180,000 per batch, which sits mid-range in the cited $100K–$300K band.

• Gross profit per patient: $373,000 minus $180,000 = $193,000, a 51.7% gross margin.
• At 120 infusions in the first full commercial year: $44.8M revenue, $23.2M gross profit.
• Against a late-stage annual burn of $60M–$90M across R&D and SG&A: still meaningfully loss-making.
• Break-even therefore requires roughly 400–500 infusions per year, not a better per-unit margin.

That is the whole strategic argument of an autologous cell therapy company in four lines. Break-even is a volume and capacity problem, not a pricing problem. Which means the questions that actually determine whether the company works are: how many treatment centres can you certify, how fast can your CDMO turn a batch, what is your manufacturing failure rate, and how many eligible patients does your indication contain. Price is close to fixed by payers and precedent. Volume is the variable you control.

Model those four drivers explicitly and you will have a financial section that reads as though it was written by someone who has thought about the business. Our bespoke business plan service builds this as a driver-based Excel model rather than a revenue line with a growth percentage attached.

Revenue before product revenue

Most companies in this sector never sell a dose. They sell the asset. Plan for the routes that actually pay:

• Out-licensing and regional rights. Upfront payment, development and commercial milestones, then royalties. For most immuno-oncology companies this is the realistic exit, and it should shape which data you generate and in what order.
• Platform partnerships. If you have a platform rather than a single asset, discovery collaborations with large pharma produce funded FTEs plus milestones and validate the technology.
• Non-dilutive grants. SBIR, Innovate UK, charity funders. Not revenue, but it is capital that does not price your equity.
• Research-use-only reagents or assays. A modest bridge that some platform companies run alongside the therapeutic programme.

Iovance Biotherapeutics is the instructive case: a tumour-infiltrating-lymphocyte company that crossed from development-stage biotech to commercial oncology company in 2024 on FDA accelerated approval of Amtagvi (lifileucel) for unresectable or metastatic melanoma. That crossing took well over a decade and enormous capital. It is achievable. It is not fast, and no honest plan should pretend otherwise.

Market Size, And Why The Published Numbers Disagree

Search for the size of the cancer immunotherapy market and you will find, for the same year, estimates of $124.09B, $136.39B, $150.25B, $153.27B, $158.42B and $253.48B. All 2025. All from established research houses. That is a spread of more than 2x on the same question.

Most business plans respond by picking the largest number and citing it as fact. This is a mistake, because the investor reading your plan has seen the others. Showing the range, and stating which definition you are using and why, is a credibility signal that costs you nothing and separates you from nearly every other deck in the pile.

Why the estimates diverge

• Scope of "immunotherapy". Include checkpoint inhibitors like Keytruda and Opdivo and the number is enormous, because those two products alone carry the category. Restrict to cell and gene therapy and it collapses.
• Immuno-oncology as a narrower cut was put at $106.92B for 2025 with roughly 13% annual growth (Startup Savant, 2025), which is a different question from the broader immunotherapy market.
• List price versus net revenue. Some houses model gross list prices, which overstates realised revenue by a wide margin in the US.
• Forecast horizon. A 2033 endpoint and a 2035 endpoint are not comparable, and CAGRs quoted range from 8.11% to 11.95% depending on both base year and definition.

Anchor figures worth citing directly: Grand View Research puts the market at $153.27B in 2025 reaching $305.80B by 2033 at a 9.02% CAGR. Precedence Research forecasts $367.63B by 2035 at 8.11%. Market.us uses 11.8% for 2025 to 2034. At the top end, a forecast of $700.09B by 2034 at 11.95% has circulated widely.

What to do with this in your plan

Do not lead with the total addressable market. A $153B TAM is not evidence of anything, because you are not competing for $153B. You are competing for the addressable slice of one indication at one line of therapy.

Build the number bottom-up instead: eligible patients in your indication, at your line of therapy, in your launch geographies, multiplied by a realistic treatment rate and a net price after payer discounts. That number will be dramatically smaller and dramatically more persuasive. A defensible $400M serviceable market with a clear route to 15% share is a fundable story. A $153B TAM with a hand-waved 1% share is not, and the reader has seen the 1% slide four hundred times.

Structurally, the field is crowded but far from consolidated. Named clinical-stage players give useful comparators for positioning: Achilles Therapeutics targets clonal neoantigens with its PELEUS bioinformatics platform, running the CHIRON trial in non-small cell lung cancer and THETIS in melanoma. Adaptimmune works on engineered TCR therapies. Dragonfly Therapeutics builds tri-specific NK cell engagers on its TriNKET platform. Umoja Biopharma is pursuing in vivo CAR-T so the engineering happens inside the patient rather than in a facility, which would dissolve the manufacturing cost problem described above if it works. Vironexis uses AAV delivery for one-time dosing. Name the two or three whose approach most resembles yours and explain, specifically, why yours is different. Vague differentiation reads as no differentiation.

Questions Founders Ask Before They Write The Plan

Do you need your own GMP facility to develop a CAR-T?

No, and at seed stage you almost certainly should not. Building GMP capacity consumes capital that should be buying data, and it converts a science risk into a construction risk. Use a CDMO, and treat the relationship as a strategic dependency rather than a purchase order. Book capacity twelve to eighteen months ahead of when you need it. The counter-argument arrives later: at commercial scale, per-patient manufacturing costs of $100K–$300K make in-housing attractive, and several companies have brought manufacturing back in after approval. That is a Series C decision, not a seed one.

Why is CAR-T so expensive?

Because one batch treats one patient. Every other pharmaceutical product amortises development, facility and quality costs across enormous batch volumes. An autologous cell therapy cannot. Add individualised labour, which is over half of manufacturing cost, plus closed-system equipment and patient-specific QC testing, and estimates of $250,000 to $450,000 per infusion follow arithmetically. The price is not a margin story. It is a structural consequence of the manufacturing model, which is precisely why allogeneic and in vivo approaches attract so much venture capital.

How long from bench to IND?

Roughly 30 to 36 months for a well-funded, well-scoped programme. IND-enabling studies alone take about 18 months. Add the licensing, freedom-to-operate and proof-of-concept work in front of them and three years is a realistic plan. Anyone promising 12 months has either not started the tox work or is not counting it.

Can a startup get a product approved without running its own trials?

Not to a BLA or a centralised EMA authorisation. But EU hospital exemption under Article 28 lets a hospital manufacture and administer a custom-made, non-routine ATMP for an individual patient within its own Member State, without central authorisation. Nineteen of 27 Member States have an operational framework. It generates genuine clinical experience while a formal programme runs in parallel. It is a bridge, not a destination.

What do investors want to see that most plans leave out?

Four things, in our experience reviewing plans in this sector. A named regulatory strategy with a booked or completed pre-IND meeting. A named CDMO with a capacity conversation actually under way. A bottom-up patient-based market model rather than a TAM slide. And an honest burn chart that reaches the next value inflection point with a margin of error built in. The plans that fail are rarely wrong about the science. They are wrong about the money.

Is an SBIR grant worth the application effort?

For most preclinical immuno-oncology companies, yes. Stacking Phase I, Phase II and a Phase IIB Bridge Award can reach around $6.7M of non-dilutive capital. Priced at seed-stage dilution, that money is worth several times its face value, and NCI review feedback is substantive. The applications are demanding and the deadlines are fixed at 5 January, 5 April and 5 September, so the work has to be planned rather than squeezed in.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These mockups use the gate-based structure described above rather than a conventional revenue ramp, which is how a preclinical therapeutics plan should be built.

What's In The Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and regulatory landscape
• Customer Analysis — Target demographics, pain points, and spending patterns
• Competitor Analysis — Local competitive mapping and your differentiation strategy
• Marketing Plan — Channels, messaging, and customer acquisition strategy
• Operations Plan — Day-to-day workflows, staffing structure, and key milestones
• Management Team — Founder bios, advisory board, and key hires planned

For cancer immunotherapy specifically, we adapt several of those sections rather than leaving you to force a therapeutics company into a retail skeleton. Industry Analysis becomes a bottom-up patient-based market model plus the regulatory route. Operations Plan becomes the CMC and CDMO strategy. Customer Analysis splits into prescribers, treatment centres and payers, because in this sector the person who chooses, the site that delivers and the party that pays are three different entities with three different objections. Competitor Analysis is framed around modality and target rather than geography.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements. For preclinical companies we build it as a burn-to-gate model with the capital requirement attached to each regulatory milestone, which is what investors in this sector actually diligence.

If you would rather start from the structure and fill it in yourself, the free business plan template is a reasonable starting point. If you want the research done, see market research and content, or read our client case studies for finished examples. Founders working on adjacent modalities may also want the immunotherapy drug business plan template, which covers the same regulatory route from a drug-development rather than cell-therapy angle.

Frequently Asked Questions

Useful Links & Resources

These links were preserved from the live page so important references and partner links are not lost during the page refresh.

• Facebook
• Instagram
• LinkedIn
• YouTube